Examining the Combination of Cefixime and Amoxicillin/Clavulanate against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolates.

Thelen, Haedi; Dilworth, Thomas J; Mercier, Renée-Claude

Thelen, Haedi; Dilworth, Thomas J; Mercier, Renée-Claude.

Affiliation

Thelen H; Department of Pharmacy Practice and Administrative Sciences, University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA.
Dilworth TJ; Department of Pharmacy, Advocate Aurora Health Milwaukee, Milwaukee, Wisconsin, USA.
Mercier RC; Department of Pharmacy Practice and Administrative Sciences, University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA.

Chemotherapy ; 67(4): 261-268, 2022.

Article in En | MEDLINE | ID: mdl-36417841

Subject(s)

Escherichia coli Infections; Urinary Tract Infections; Humans; Cefixime/pharmacology; Cefixime/therapeutic use; Escherichia coli; beta-Lactamases; Amoxicillin-Potassium Clavulanate Combination/pharmacology; Amoxicillin-Potassium Clavulanate Combination/therapeutic use; Microbial Sensitivity Tests; Escherichia coli Infections/drug therapy; Urinary Tract Infections/drug therapy

Key words

Antibiotic resistance; Beta-lactam antibiotics; Beta-lactamase; Escherichia coli; Urinary tract infection

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Tract Infections / Escherichia coli Infections Limits: Humans Language: En Journal: Chemotherapy Year: 2022 Document type: Article Affiliation country: United States Country of publication: Switzerland

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google